MARKET

TRVI

TRVI

Trevi Therapeutics
NASDAQ
12.52
-0.04
-0.32%
After Hours: 12.28 -0.24 -1.92% 17:30 12/31 EST
OPEN
12.48
PREV CLOSE
12.56
HIGH
12.69
LOW
12.33
VOLUME
974.34K
TURNOVER
--
52 WEEK HIGH
14.39
52 WEEK LOW
3.472
MARKET CAP
1.61B
P/E (TTM)
-33.7284
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at TRVI last week (1222-1226)?
Weekly Report · 12/29/2025 09:07
Weekly Report: what happened at TRVI last week (1215-1219)?
Weekly Report · 12/22/2025 09:07
Trevi Therapeutics Is Maintained at Buy by Stifel
Dow Jones · 12/19/2025 15:04
Trevi Therapeutics Price Target Raised to $18.00/Share From $15.00 by Stifel
Dow Jones · 12/19/2025 15:04
Stifel Maintains Buy on Trevi Therapeutics, Raises Price Target to $18
Benzinga · 12/19/2025 14:54
Trevi Therapeutics price target raised to $18 from $15 at Stifel
TipRanks · 12/19/2025 12:55
TREVI THERAPEUTICS INC <TRVI.O>: STIFEL RAISES TARGET PRICE TO $18 FROM $15
Reuters · 12/19/2025 12:13
Weekly Report: what happened at TRVI last week (1208-1212)?
Weekly Report · 12/15/2025 09:07
More
About TRVI
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), chronic cough in patients with non-IPF interstitial lung disease, and refractory chronic cough. Haduvio is an oral extended-release (ER) formulation of nalbuphine. Nalbuphine is a mixed kappa-opioid receptor agonist and mu-opioid receptor antagonist. It has conducted a Phase II clinical trial and an open-label extension study of Haduvio in pruritus in patients with prurigo nodularis and a Phase IIb/III clinical trial. The Company’s Haduvio development programs include Chronic Cough in IPF Program, RCC Program, and Prurigo Nodularis Program. The Company’s subsidiary is Trevi Therapeutics Limited.

Webull offers Trevi Therapeutics Inc stock information, including NASDAQ: TRVI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TRVI stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading TRVI stock methods without spending real money on the virtual paper trading platform.